US 8589182

I'll search for authoritative information on this specific patent number.

Let me verify whether there is any 2026 Federal Circuit docket activity specifically tied to this patent number.

Summary: US Patent 8,589,182 B1

Search scope note: I queried for this number specifically (US 8,589,182 / application 13/595,676). Results for look‑alike numbers (e.g., US 8,457,988 B1 / US 8,547,988 B1, US 8,737,963, US 7,668,730) appeared in the same family and were excluded from the profile below except where they clarify family lineage. The authoritative patent text supplied in the prompt matches the public records I retrieved.

Bibliographic data

Continuity: This patent is a continuation of Ser. No. 13/013,680 (filed 2011‑01‑25, abandoned), which is a continuation of Ser. No. 12/704,097 (filed 2010‑02‑11, issued as US 7,895,059), which is a continuation of Ser. No. 10/322,348 (filed 2002‑12‑17, issued as US 7,668,730). All intermediate applications are incorporated by reference.

Abstract (verbatim)

"A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug."

The specification frames the "sensitive drug" as sodium oxybate / gamma hydroxybutyrate (GHB), marketed as Xyrem® (sodium oxybate oral solution) for cataplexy in narcolepsy, and states the invention is also useful for Schedule II–V controlled substances.

Plain-language overview of the independent claims

Claim 1 — Database-centric treatment method (broadest)

A method of treating a narcoleptic patient with a prescription drug that has potential for misuse/abuse/diversion, where the drug is sold or distributed by the company that obtained approval for its distribution. It requires, using a computer processor:

1. Receiving into a single company database — from any and all patients prescribed the company's drug — all prescriptions for that drug;
2. Entering data identifying the narcoleptic patient;
3. Entering data identifying any and all physicians/prescribers and showing they are authorized to prescribe;
4. Entering and maintaining records of abuse/misuse/diversion by the patient or prescriber; and
5. Checking for abuse against the database and authorizing filling only if (a) there is no record of such incidents, or (b) if a record exists, the database shows the incidents were investigated and do not involve abuse/misuse/diversion.

Claim 8 — Single-trademark variant

Essentially the same five-step architecture as claim 1, but the drug is defined as one "sold or distributed under a single trademark," and the stored data is framed as information that "may suggest" abuse/misuse/diversion (a slightly lower evidentiary threshold than claim 1's "indicates"). The abuse-check/authorization condition is otherwise parallel.

Claim 15 — Single-manufacturing-site + GHB/cataplexy variant

Adds two substantive limitations to the claim 1 framework:

• The drug was manufactured at a single manufacturing site;
• The method includes providing the drug to the patient to treat them, and the drug is expressly a GHB drug product that treats cataplexy in the narcoleptic patient.
  (Note: it recites "the physician or other prescriber" in the singular, rather than "any and all.")

Claim 19 — Multi-control pharmacy-enrollment variant

The most detailed independent claim, combining distribution controls:

• Receives into a single database all prescriptions received at a pharmacy, for a single drug sold/distributed by the company that obtained distribution approval;
• Requires that the pharmacy be permitted to distribute the drug based on two or more of: processing a prescription enrollment form; agreeing to document adverse events; providing educational materials; verifying the drug is medically necessary;
• Requires entering prescriber data including verifying that the prescriber's DEA number and state license are current and that there are no pending disciplinary actions;
• Requires verifying two or more of: patient name; patient address; that the patient received educational material; the quantity; and dosing directions — before providing the drug;
• Retains the abuse/misuse/diversion record-keeping and abuse-check/authorization step.

Claim 26 — Inventory reconciliation (depends from claim 1)

Adds identifying prescription and patient information and using it for reconciling inventory for the drug before shipments for a day or other time period are sent.

Dependent claims generally add: delivering the drug to treat the patient (2, 9, 20); pharmacy entering data (3, 10, 16, 21); selectively blocking shipment (4, 11, 17, 22); blocking shipment based on an associated abuse pattern (5, 12, 18, 23); GHB drug product (6, 13, 24); and GHB treating cataplexy (7, 14, 25).

Litigation and post-grant proceedings found for this specific patent

Google Patents and PTAB records tie US 8,589,182 to the following:

• IPR2015‑00545 — [Amneal Pharmaceuticals LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%20LLC), Par Pharmaceutical, Inc., and Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc. Filed 2015‑01‑08; institution decision 2015‑07‑29; Final Written Decision 2016‑07‑27; all claims 1–26 challenged; listed appeal number 2017‑1671. (docketalarm, Patexia)
• IPR2015‑01813 — Wockhardt Bio AG et al. v. Jazz Pharmaceuticals, Inc. Filed 2015‑08‑27; institution decision 2015‑10‑30; FWD 2016‑07‑27. (GreyB/IPVerse)
• CBM2014‑00153 — filed but Not Instituted (Procedural) per Google Patents.
• District court suits (New Jersey D.N.J. and E.D.N.Y.) listed on the Google Patents page: 2:13‑cv‑07884; 2:14‑cv‑03235; 2:14‑cv‑04467; 2:14‑cv‑07757; 2:15‑cv‑05619; 2:15‑cv‑06548; 2:17‑cv‑05487; and E.D.N.Y. 2:17‑cv‑04439.

CAFC 2026 docket check — result and uncertainty

I found no 2026 Federal Circuit docket entry naming US 8,589,182. My searches for 2026 Federal Circuit activity returned only:

• Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, Nos. 2024‑2274/2277/2278, decided May 6, 2025 (reversed‑in‑part, vacated‑in‑part, remanded) — concerning the '782 opioid/oxybate‑related patent and sustained‑release oxybate formulation patents, not the '182 patent. (CAFC opinion, Justia)
• 2026 Federal Circuit opinions/orders on unrelated patents (e.g., Headwater Research v. Verizon; Rare Breed Triggers; the March 2026 calendar).

Explicit uncertainty: I do not have authoritative information on the outcome of the appeal from the Amneal/Par/Wockhardt IPR FWDs (listed as appeal 2017‑1671). Earlier searches surfaced a 2026 Federal Circuit summary covering other patents but no 2026 activity for the '182. If a 2026 CAFC docket exists for this patent, it did not appear in the sources I could access, and I will not assert one exists.

Key caveats

1. Number discipline: All figures above refer literally to US 8,589,182 B1 (application 13/595,676). Sibling patents in the same family (US 7,668,730; US 7,765,106; US 7,765,107; US 7,797,171; US 7,895,059; US 8,457,988; US 8,731,963) are separate patents with separate claims and should not be conflated with this one.
2. Status: "Expired – Fee Related" indicates lapse for non‑payment of maintenance fees, not invalidity. One source table lists a sibling (US 11/097,651, "Active," 2026‑07‑19), which should not be read as the status of the '182.
3. Assignee chain: The patent lists Jazz Pharmaceuticals, Inc. as assignee; prosecution references show Orphan Medical, Inc. and JPI Commercial, LLC as earlier assignees, and assignment records show security interests to Barclays Bank PLC, Bank of America, N.A., and U.S. Bank National Association. These are recorded security agreements, not ownership changes.

Sources: Google Patents US8589182B1; FreePatentsOnline 8589182; Justia Patents 8589182; PTAB records as linked above.

I'll research litigation involving US patent 8589182 using multiple sources.

Let me search for the specific district court cases and IPR outcomes.

Let me verify the specific district court case numbers and parties.

Based on my research, here is what I found regarding litigation involving US Patent 8,589,182 B1 (listed as "US8589182" — the patent titled "Sensitive drug distribution system and method," originally assigned to Orphan Medical, later Jazz Pharmaceuticals, Inc.).

Important preliminary note

US 8,589,182 ("the '182 patent") is one member of the "730 patent family" of Xyrem® (sodium oxybate) distribution patents. It was a continuation filed Aug. 27, 2012, claiming priority to Dec. 17, 2002, and it expired (per Google Patents) on/around Dec. 17, 2022 ("Expired – Fee Related"). Google Patents' "Family has litigation" data covers the whole family (15 applications), so not every family case necessarily asserted the '182 patent specifically. Where I could confirm the '182 patent itself was at issue, I say so explicitly; where I could not, I flag it.

1. PTAB — Inter Partes Review (confirmed to involve the '182 patent)

A. [Amneal Pharmaceuticals LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%20LLC) and Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Forum: USPTO Patent Trial and Appeal Board
• Case No.: IPR2015-00545
• Patent: U.S. 8,589,182 B1
• Filed: Jan. 8, 2015
• Petitioners: Amneal Pharmaceuticals LLC; Par Pharmaceutical, Inc.
• Patent Owner: Jazz Pharmaceuticals, Inc.
• Outcome: Final Written Decision (July 27, 2016) held all challenged claims of the '182 patent unpatentable as obvious over the "Advisory Committee Art" (FDA Xyrem advisory-committee materials). Jazz's Request for Rehearing was denied (Decision dated Dec. 19/22, 2016). The decision was affirmed on appeal.
• Appeal: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 2017-1675 (Fed. Cir. July 13, 2018), 895 F.3d 1347 — Federal Circuit affirmed the PTAB (holding the FDA Advisory Committee materials were a publicly accessible "printed publication" and proper prior art).
• Sources: Docket Alarm IPR2015-00545 docket; PTAB Decision Denying Rehearing (Paper 73); Duane Morris and Knobbe Martens case notes; Fed. Cir. opinion (govinfo 17-1675).

B. Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc.

• Forum: USPTO PTAB
• Case No.: IPR2015-01813
• Patent: U.S. 8,589,182 (Respondent App. No. 13/595,676)
• Filed: Aug. 27, 2015
• Petitioner: Wockhardt Bio AG
• Patent Owner: Jazz Pharmaceuticals, Inc.
• Institution Decision: Oct. 30, 2015
• Outcome/Status: Terminated July 27, 2016 (Wockhardt settled; Duane Morris represented Wockhardt and confirmed the case settled prior to the Federal Circuit decision). Reported status: "Final Written Decision."
• Sources: GreyB/IPVerse case detail IPR2015-01813; Duane Morris alert.

(The family data also lists a CBM2014-00153 marked "Not Instituted – Procedural," but I could not confirm it targeted the '182 patent specifically.)

2. District Court patent-infringement (ANDA) litigation

Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC and Par Pharmaceutical, Inc.

• Court: U.S. District Court for the District of New Jersey
• Case No.: Civil Action No. 13-391 (ES)(JAD) (Consolidated)
• Defendants: Amneal Pharmaceuticals, LLC; Par Pharmaceutical, Inc.
• Relevance to '182: The parties' Joint Claim Construction and Prehearing Statement expressly lists U.S. 8,589,182 ("the '182 patent") among the "730 patent family" patents-in-suit, brought under 35 U.S.C. § 271(e)(2) over the defendants' ANDAs for generic Xyrem.
• Source: Docket Alarm (D.N.J. 2:13-cv-00391, doc. 83, Joint Claim Construction Statement).

Additional D.N.J. cases: Google Patents' litigation data for the '182 family lists these New Jersey District Court filings, which I could not individually confirm as asserting the '182 patent specifically (I was unable to retrieve party-by-party details for each before running out of search capacity):

• 2:13-cv-07884
• 2:14-cv-03235
• 2:14-cv-04467
• 2:14-cv-07757
• 2:15-cv-05619
• 2:15-cv-06548
• 2:17-cv-05487
• (also New York Eastern District Court: 2:17-cv-04439)

These are consistent with Jazz's serial ANDA suits against generic sodium-oxybate applicants (Roxane/Hikma, Amneal, Par, Lupin, Wockhardt, Ranbaxy, Watson, Mallinckrodt). Treat the case numbers as reliably reported by Google Patents, but the party/date/outcome details as unverified.

Roxane litigation (context): Jazz's lead case against Roxane Laboratories was Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., Civil Action No. 10-6108 (D.N.J.), which concerned the earliest "original patents-in-suit." The '182 patent issued later (Nov. 19, 2013) and appears in related/consolidated New Jersey actions rather than the original 2010 complaint. I could not confirm a discrete Roxane complaint asserting the '182 patent.

3. Antitrust / multi-district litigation (patent listed as at issue)

In re Xyrem (Sodium Oxybate) Antitrust Litigation — N.D. Cal. (MDL; consolidated), plus related cases such as:

• New York State Teamsters Council Health and Hospital Fund v. Jazz Pharmaceuticals, Inc., No. 3:20-cv-04056 (N.D. Cal.), filed June 18, 2020 — cause: 15:15 Antitrust; assigned to Judge Richard G. Seeborg. U.S. 8,589,182 is listed among the patents cited/at issue.
• Defendants across the MDL include Jazz Pharmaceuticals, Roxane/Hikma, Amneal, Par, Lupin, Ranbaxy, Wockhardt, Watson, and Mallinckrodt.
• Status (as of Jazz's disclosures): Class certification granted (May 12, 2023, then amended Oct. 18, 2024); summary-judgment motions decided Aug. 26, 2024; trial rescheduled for May 19, 2025; settlements reached with Amneal and Lupin (final approval April 17, 2024).
• Sources: DrugPatentWatch case page (3:20-cv-04056); Jazz Pharmaceuticals SEC/investor disclosures; N.D. Cal. class-action complaint (cand.365967).

Note: These are antitrust actions in which the Xyrem patent family (including the '182 patent) is cited background, not patent-infringement suits on the '182 patent itself.

Summary table

Caveats and confidence

• High confidence: the two PTAB proceedings (IPR2015-00545 and IPR2015-01813) were directed at US 8,589,182 specifically, and the Federal Circuit affirmance (July 13, 2018) is well documented. The '182 patent is now expired.
• Lower confidence: the exact party/date/outcome mapping for the D.N.J. case numbers 2:13-cv-07884, 2:14-cv-03235, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, and E.D.N.Y. 2:17-cv-04439. These come from Google Patents' family-litigation data, which is not patent-specific, and I could not verify each docket before exhausting my search budget. I did not auto-correct or infer the numbers.
• The '182 patent shares a specification with U.S. 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; and 8,731,963; the Federal Circuit's July 13, 2018 decision disposed of all of them together, which is why many sources describe the ruling in family-level terms.

If you need the individual party names, filing dates, and dispositions for each of the eight unverified district-court dockets, those would require pulling each PACER/Docket Alarm record directly — I'd recommend retrieving them before relying on them in any filing.

I'll research the AIA trial proceedings on this patent. Note a key tension up front: the structured ODP block says "no PTAB activity on file," but the patent's own Google Patents page lists IPR2015-00545, IPR2015-01813, and CBM2014-00153. Let me investigate.

Good — rich results. Let me pin down the IPR2015-01813 outcome, the CBM2014-00153 panel/date, and the Federal Circuit disposition of the appeals.

⚠️ Source conflict flagged up front: The structured "PTAB proceedings on file" block (USPTO ODP) says no AIA trial proceedings exist for this patent. That ingest is incomplete/wrong. The patent's own Google Patents page, the PTAB docket, and the Federal Circuit record all show three AIA proceedings on US 8,589,182 (IPR2015‑00545, IPR2015‑01813, CBM2014‑00153). I'm treating the ODP block as stale and sourcing the list from the public record. I also note an internal inconsistency in the Patent Summary: the "Expired – Fee Related / anticipated expiration 2022‑12‑17" status sits awkwardly beside the fact that all 26 claims were canceled by IPR and the cancellation was affirmed on appeal (2018‑07‑13). The maintenance‑fee/expiration status is a red herring — the claims are dead by judgment, not just by lapse.

Proceedings overview

There are 3 AIA trial proceedings on the '182 patent: 2 IPRs (both of which invalidated all 26 claims, affirmed on appeal) and 1 CBM (institution denied). There are 0 active proceedings, 0 sustained claims, and 0 untested claims. Bottom line for a defendant: the '182 is a corpse. Every one of claims 1–26 was held unpatentable over the "Advisory Committee Art" (ACA), the Federal Circuit affirmed, and a certificate canceling the claims followed. If a demand letter cites US 8,589,182 — or claims 1–26 specifically — it is citing canceled claims. That is not merely a weak case; asserting canceled claims is sanction-bait.

IPR2015-00545 — [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) & Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review
• Filed: 2015-01-08
• Status: Final Written Decision (2016-07-27) — all claims unpatentable; affirmed on appeal.
• Judge panel: Jacqueline Wright Bonilla, Brian P. Murphy (panel author), Jon B. Tornquist.
• Petition grounds: Claims 1–26 (all claims), single ground — unpatentable under 35 U.S.C. § 103 as obvious over the "Advisory Committee Art" (ACA), Exs. 1003–1006: (1) FDA Advisory Committee Transcript and Slides; (2) FDA Preliminary Clinical Safety Review; (3) Xyrem Briefing Booklet; (4) Xyrem Video and Transcript. No § 112 or § 101 ground was relied on for institution.
• Institution decision: Instituted 2015-07-29 on the single ACA § 103 ground for claims 1–26. There was a real party‑in‑interest skirmish (the panel authorized a special RPI‑only response/reply, Papers 12/17/18) but it did not defeat institution.
• Final Written Decision (2016-07-27): Verbatim disposition: "we determine Petitioner has shown by a preponderance of the evidence that claims 1–26 of the '182 patent are unpatentable." That is every claim — all four independents (1, 8, 15, 19) and all dependents (2–7, 9–14, 16–18, 20–26). The Board also dismissed Petitioner's Motion to Exclude and Motion to Allow Late Filing as moot. Key predicate finding (later affirmed): the ACA materials were publicly accessible on an FDA website listed in a May 14, 2001 Federal Register Notice no later than 2001-10-04, more than two months before the 2001-12-17 critical date — and a person of ordinary skill (a pharmacist or computer scientist) would have been motivated to locate them. (FWD PDF via Docket Alarm)
• Settlement / termination: None as to Amneal/Par.
• Appeal: Yes — consolidated Fed. Cir. Nos. 2017‑1671, ‑1673, ‑1674, ‑1675, ‑1676, ‑1677, ‑2075 (Jazz as appellant). Affirmed 2018-07-13, Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018) (Newman, Lourie, Reyna; Lourie, J.). The court held the ACA materials were printed publications under pre‑AIA § 102(b) (breadth of Federal Register dissemination, duration on the FDA website, no expectation of confidentiality, rejection of any "indexing/searchability" requirement), affirmed the constructions of "periodic reports" and "information identifying," and affirmed obviousness. (GovInfo opinion PDF; IPWatchdog summary)
• Defensive value: Decisive. Claims 1–26 of the '182 were canceled and the cancellation is final and non‑appealable. Any infringement theory built on any claim of this patent is untenable.

IPR2015-01813 — Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (filed as a joinder petition under § 315(c)/§ 42.122(b))
• Filed: 2015-08-27 (accorded filing date Paper 5)
• Status: Final Written Decision / terminated — the joined challenge knocked out claims 1–26; the proceeding itself was terminated as to Petitioner Wockhardt Bio AG after settlement.
• Judge panel: Institution/joinder decision by Jacqueline Wright Bonilla, Susan L. C. Mitchell, and Brian P. Murphy (author). Aggregators list the closing/FWD panel for 01813 as Bonilla, Murphy, Tornquist — treat the exact closing panel as unconfirmed.
• Petition grounds: Claims 1–26, on the identical ground already instituted in IPR2015-00545 — § 103 over the same ACA exhibits (Exs. 1003–1006). The Board expressly noted Wockhardt's Petition was based on "the same arguments, evidence, and ground of unpatentability" and was "otherwise identical" to the Amneal/Par petition.
• Institution decision: Instituted and joined 2015-10-30 (Paper 44, "Decision Institution of Inter Partes Review and Grant of Motion for Joinder"), joining the case into IPR2015-00545. (Decision PDF via Docket Alarm)
• Final Written Decision: The joined proceeding's FWD (2016-07-27, in IPR2015-00545) invalidated claims 1–26; the '182 went down with the case. Aggregators (Patexia, IP Verse) record a 2016‑07‑27 "termination/FWD" date for 01813 — that reflects the joined proceeding's resolution.
• Settlement / termination: Settled. Jazz announced a 2016-04-18 settlement with Wockhardt (license to launch generic Xyrem on or after 2025‑12‑31, terms confidential). Jazz requested authorization for joint termination motions (covering IPR2015‑01813, ‑01814, ‑01815, ‑01816, ‑01818, ‑01820 and IPR2016‑00370, and as to Wockhardt in the ‑00545/-00546/-00547/-00548/-00551/-00554 family). The Board entered an Order Terminating the Proceedings as to Petitioner Wockhardt Bio AG, dated 2016-05-05 (Paper 11). (Termination order docket entry) The settlement agreement was filed under seal as required by § 317(b)/§ 42.74(b) — its terms are confidential.
• Appeal: No separate Wockhardt appeal that I can confirm for the '182; the controlling appellate ruling is the 2017‑1671 affirmance of the IPR2015‑00545 FWD.
• Defensive value: This was a me-too/joinder attack, not an independent second theory. It adds estoppel exposure for Wockhardt but no new defensive ground. Its practical significance is the settlement optics — Jazz bought peace on the '182 family through licensing rather than winning on the merits.

CBM2014-00153 — Amneal Pharmaceuticals, LLC & Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Type: Covered Business Method review (AIA § 18)
• Filed: 2014-07-09
• Status: Not Instituted — Denied (2015-01-13). (PTO Litigation Center Report, 2014-07-10)
• Judge panel: Not confirmed in the sources I retrieved — I will not name a panel I cannot verify.
• Petition grounds: Claims 1–26 challenged under 35 U.S.C. §§ 101, 102(b), and 103(a). The § 101 hook was the post-Alice abstract‑idea theory, riding on the CBM "financial product or service" gateway.
• Institution decision: Denied 2015-01-13, together with sibling CBMs CBM2014‑00149 ('059), ‑00150 ('988), and ‑00151 ('730). The Board held the claims do not qualify as a "covered business method patent" under AIA § 18(d)(1) because they are not directed to a "financial product or service." Reasoning: the '182's independent claim preambles recite a "method of treatment of a narcoleptic patient…," and the body recites access‑controls on the drug; the "sold or distributed by a company that obtained approval" clause is "little more than a contextual description of a company approved by the FDA," not a method step in the practice/administration/management of a financial product or service. The Board also rejected the "used in commerce" expansion and the Class 705 classification argument. See Case CBM2014‑00153 (Patent 8,589,182 B1), Denying Institution at 4. (Decision PDF via PTAB Trial Blog; Carlson Caspers summary)
• Final Written Decision / Settlement / Appeal: N/A (never instituted).
• Defensive value: Historically it established that a pharma REMS/distribution patent is not CBM‑eligible in the PTAB's view — so a defendant cannot use the CBM track here. But this is moot for the '182 because the IPRs already canceled the claims on § 103.

Strategic summary

Claim status. All 26 claims of US 8,589,182 are CANCELED. There are no sustained claims and no untested claims — the '182 had only 26 claims and every one was challenged and invalidated. The invalidating ground was a single § 103 ground (ACA materials alone), held unpatentable at 2016‑07‑27 and affirmed at 895 F.3d 1347 (Fed. Cir. 2018‑07‑13). The ACA "printed publication" holding is now binding Federal Circuit law that applies across the entire Xyrem distribution family (the Fed Cir affirmance covered '730, '106, '107, '059, '182, '988, and '963). For sibling patents with the same written description and similar claims, that opinion is the controlling template.

Estoppel landscape. Under 35 U.S.C. § 315(e)(2), the IPR petitioners — Amneal and Par — are estopped in civil actions from asserting, as to claims 1–26, any ground they raised or reasonably could have raised in IPR2015‑00545. Wockhardt joined the proceeding but was terminated as a petitioner on settlement (2016‑05‑05); whether pre‑FWD termination for a settling joined petitioner extinguishes § 315(e)(2) estoppel is a wrinkle I would not over‑state — the safer reading for a new defendant is that Wockhardt is not a useful source of estoppel protection. Critically, estoppel runs one way: a new defendant who was not a petitioner, RPI, or privy is not bound, so it could theoretically raise any ground. But there is nothing left to raise — the claims are canceled. The only estoppel‑relevant question for a new defendant is whether it faces a demand on a sibling patent (e.g., '963, or the post‑2013 Jazz "Sensitive drug distribution systems and methods" applications such as US 11,456,081), where the ACA + Korfhage art and the Fed Cir's printed‑publication holding remain available.

Pattern signals. (1) Same‑petitioner behavior: Amneal (with Par) filed a full portfolio attack — six IPRs and four CBMs — and Jazz won the CBM gate but lost the IPRs on the merits. Wockhardt then filed copycat joinder petitions (IPR2015‑01813 et al.) rather than independent grounds, and settled. (2) Patent‑owner behavior: Jazz appealed the IPR losses (2017‑1671 et al.), took the printed‑publication fight all the way to the Federal Circuit, and lost. Jazz did not pursue PTAB appeals aggressively beyond that — the family's invalidity was effectively conceded after the 2018 affirmance, and Jazz pivoted to settlements/licenses (Wockhardt and Ranbaxy, 2016; and the broader Xyrem generic‑entry litigation culminating in a January 1, 2023 to December 31, 2025 generics timeline). (3) No defensive aggregator (e.g., Unified Patents) appears in the chain for the '182 — the attacks came from commercial ANDA filers. (4) Note the IPR2015‑00545 appeal had a Par dropout — "Jazz and Par reached a settlement during the pendency of this appeal, and accordingly Par is no longer a party" — a reminder that even the losing petitioners settled mid‑appeal.

Recommended next steps

1. If you are a defendant facing a demand or suit that cites US 8,589,182 (any of claims 1–26): the patent is unenforceable as to those claims. Link the dispositive document directly — the Final Written Decision of 2016‑07‑27 in IPR2015‑00545, which states: "we determine Petitioner has shown by a preponderance of the evidence that claims 1–26 of the '182 patent are unpatentable" — and the Fed. Cir. affirmance at 895 F.3d 1347 (2018‑07‑13). (FWD PDF; Fed. Cir. opinion) A Rule 11 / § 285 posture is available if a plaintiff persists after notice of the cancellation.

2. Confirm the cancellation certificate. Pull the USPTO's certificate of cancellation for US 8,589,182 (issued after the 2018 mandate) via PTAB E2E (https://ptacts.uspto.gov) and the patent's USPTO PatentCenter file wrapper. This is your cleanest single exhibit. Do not rely on the "Expired – Fee Related" Google Patents status — that reflects maintenance‑fee lapse and is not the reason the claims are dead.

3. No live PTAB milestones exist. There are no pending institution deadlines, oral hearings, or FWD due dates on the '182. Any ongoing exposure must be on a different patent.

4. Map the family before you rest. Because the demand may have migrated to a sibling, run the same ACA/printed‑publication analysis against: US 7,668,730; 7,765,106; 7,765,107; 7,797,171; 7,895,059; 8,457,988; 8,731,963 (all part of the same IPR sweep and Fed Cir appeal) and the later Jazz distribution patents/applications (e.g., US 11,456,081 and the 2017/2020 "Sensitive drug distribution systems and methods" filings). The Fed Cir's 2018‑07‑13 printed‑publication holding is your reusable weapon there.

5. Mind the § 315(b) clock and prior‑art estoppel if you file. For any sibling patent, one year runs from service of an infringement complaint; and if you are an ANDA filer working the Hatch‑Waxman track, sequence your IPR filing against the 30‑month stay. Also weigh Fintiv-style discretionary‑denial risk if parallel district litigation is co‑pending.

Uncertainty disclosures: I could not confirm the CBM2014‑00153 panel composition, and I could not independently verify whether the Board entered a separate FWD caption in IPR2015‑01813 versus relying on the joined IPR2015‑00545 FWD; the 2016‑05‑05 termination order and the 2016‑07‑27 aggregator date are both reported above. The Wockhardt settlement terms are confidential and are not in the record.

I'll research the assignment record for US 8,589,182 through the USPTO Assignment Center and cross-referenced sources.

Let me search for the specific assignment records and reel/frame data.

Let me try to retrieve the specific USPTO assignment records with reel/frame data.

I completed the assignment-chain research. Important limitation up front: I was able to confirm that recorded assignment events exist for this patent (via Google Patents' USPTO-derived legal-events table and corroborating SEC/credit-agreement records), but I was unable to retrieve the USPT0 Assignment Center reel/frame numbers or the correspondent-of-record fields for those events before exhausting my search budget. I will not invent reel/frame numbers. Where a field is unknown, I say so.

Inventors

Basis: All three inventors' addresses of record are in the Minneapolis–St. Paul metro, matching Orphan Medical, Inc. of Minnetonka, MN — the entity that filed the parent application Ser. No. 10/322,348 on 2002‑12‑17 and to which the original grant US 7,668,730 issued. The Xyrem® restricted-distribution program is described in the specification as Orphan Medical's program, and prosecution documents refer to "Applicant" as Orphan Medical.

Unusual-pattern check — not present / insufficient data: I found no evidence that any inventor departed the original assignee within 12 months of filing. I could not retrieve employment-departure data (no SEC Forms 3/4 or termination records located for these inventors), so I make no call on this pattern. The inventors' declaration was made while the application was Orphan‑Medical‑owned; I have no record of an inventor assignment document with a date or reel/frame.

Original assignee

Two entities must be distinguished:

• Entity named on the issued patent (US 8,589,182 B1, issued 2013‑11‑19): Jazz Pharmaceuticals, Inc. (Palo Alto, CA). This is the assignee of record printed on the face of the '182 patent.
• Entity that filed the priority application (Ser. No. 10/322,348, 2002‑12‑17): Orphan Medical, Inc. (Minnetonka, MN).

Line of business / product embodying the claims: Orphan Medical was a specialty pharmaceutical company whose lead product was Xyrem® (sodium oxybate) oral solution — the very product the claimed central-pharmacy distribution system was built to control. Orphan Medical commercialized Xyrem under a restricted-distribution program, and the claimed invention reads on that program. So the original assignee shipped a product embodying the claims.

Current status:

• Orphan Medical, Inc. — acquired, not bankrupt. Jazz Pharmaceuticals, Inc. completed its acquisition of Orphan Medical on June 24, 2005 (Jazz financed part of the purchase with $80.0M senior secured notes — see the Jazz 10‑K narrative). It ceased to be an independent public company.
• Jazz Pharmaceuticals, Inc. — operating, now a subsidiary of Jazz Pharmaceuticals plc (Ireland), NASDAQ: JAZZ. It still sells oxybate products (Xyrem®, Xywav®) and reported oxybate revenue on the order of $1.8B in its most recent filings. Not dissolved, not in bankruptcy.
• JPI Commercial, LLC — a Delaware LLC and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc. (confirmed by Jazz's Dec. 19, 2008 Amendment 3 to License Agreement, which describes "JPI COMMERCIAL, LLC … a wholly-owned subsidiary of Jazz Pharmaceuticals, Inc."). It appears as assignee of record on several sibling patents in this family (US 7,668,730; 7,765,106; 7,765,107; 7,797,171), which is consistent with an internal corporate reorganization rather than a third-party transfer.

Assignment timeline

Retrieval status: The USPTO Assignment Center records for this patent were not retrievable in full during this analysis. What follows is reconstructed from (a) Google Patents' "Reassignments" table (which is populated from USPTO assignment data), and (b) Jazz's SEC filings describing the underlying credit facilities. Reel/frame numbers are NOT verified and are omitted rather than guessed. Correspondent-of-record data was NOT retrieved for any entry. The events below are all security interests and releases, not transfers of ownership.

• Executed ~2012‑06‑12 / recorded 2014‑02‑13 — Reel/Frame unknown

  • Conveyance: Security Agreement (grant of security interest)
  • Assignor: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals International III Limited
  • Assignee: Barclays Bank PLC, as Collateral Agent
  • Correspondent: not retrieved
  • Context: Securitization — collateral grant under the June 12, 2012 Barclays-administered credit agreement (as amended Jan. 23, 2014); Jazz pledged IP as collateral for the EUSA Pharma acquisition financing.

• Executed ~2015‑06‑18 / recorded 2015‑06‑19 — Reel/Frame unknown

  • Conveyance: Security Agreement
  • Assignor: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals International III Limited; Jazz Pharmaceuticals Ireland Limited
  • Assignee: Bank of America, N.A., as Collateral Agent
  • Correspondent: not retrieved
  • Context: Securitization — replacement collateral grant under the June 18, 2015 Bank of America-administered credit agreement ($750M term A + $750M revolver).

• Recorded 2015‑07‑09 — Reel/Frame unknown

  • Conveyance: Release by Secured Party
  • Assignor: Barclays Bank PLC, as Collateral Agent
  • Assignee: Jazz Pharmaceuticals, Inc.; Jazz Pharma International Limited; Jazz Pharma International III Limited
  • Correspondent: not retrieved
  • Context: Securitization release — Barclays lien released upon refinancing of the 2012 facility (mirrors the June 2015 Bank of America grant).

• Recorded 2021‑05‑05 — Reel/Frame unknown

  • Conveyance: Release by Secured Party
  • Assignor: Bank of America, N.A.
  • Assignee: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals International III Limited; Celator Pharmaceuticals, Inc.; Cavion, Inc.; Jazz Pharmaceuticals Ireland Limited
  • Correspondent: not retrieved
  • Context: Securitization release — Bank of America lien released upon the May 5, 2021 refinancing tied to the GW Pharmaceuticals acquisition.

• Recorded 2021‑05‑05 — Reel/Frame unknown

  • Conveyance: Security Agreement
  • Assignor: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Limited; Celator Pharmaceuticals, Inc.; Cavion, Inc.
  • Assignee: U.S. Bank National Association (later U.S. Bank Trust Company, National Association, as successor Collateral Trustee)
  • Correspondent: not retrieved
  • Context: Securitization — collateral grant under the May 5, 2021 credit agreement; U.S. Bank named Collateral Trustee.

Sibling-patent note (not an assignment of the '182 itself): US 7,668,730; 7,765,106; 7,765,107; and 7,797,171 list JPI Commercial, LLC as assignee of record, suggesting an intra-family transfer from the Orphan Medical entity to JPI Commercial before those patents issued (2010). I could not locate the reel/frame, execution date, or correspondent for that transfer, and I do not assert that the '182 patent was part of it — the '182 issued (2013) in the name of Jazz Pharmaceuticals, Inc.

Also unverified: I could not confirm a discrete assignment recording for the Orphan Medical → Jazz acquisition (June 24, 2005), which in USPTO practice would typically be recorded as either an Assignment (merger) or Change of Name, nor a JPI Commercial → Jazz Pharmaceuticals, Inc. transfer. These may exist in the Assignment Center; I simply could not retrieve them.

Timeline diagram

timeline
    title Ownership of US 8589182
    2002 : Filed by Orphan Medical Inc
    2005 : Jazz Pharmaceuticals acquires Orphan Medical
    2010 : JPI Commercial LLC on sibling patents
    2013 : Patent 8589182 issues to Jazz Pharmaceuticals
    2014 : Security agreement to Barclays Bank
    2015 : Security agreement to Bank of America
         : Barclays security interest released
    2021 : Bank of America release recorded
         : Security agreement to US Bank
    2022 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. Every recorded entity in the chain is an operating pharmaceutical company or a wholly-owned subsidiary of one (JPI Commercial, LLC is expressly "a wholly-owned subsidiary of Jazz Pharmaceuticals, Inc." per Jazz's 2008 license amendment). No assignee is a licensing-only LLC with a registered-agent service address; no assignee name carries "IP / Patents / Licensing / Holdings / Ventures." The recorded conveyances (2014, 2015, 2021) are security interests, not ownership transfers, and they run to banks, not to asserters.

2. Known asserter in the chain — NOT PRESENT. No assignee matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Conversant/Mosaid, Pendrell, Innovio, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities, or any high-frequency plaintiff surfaced by Unified Patents or RPX. Jazz Pharmaceuticals is the court-recognized patent owner and competitor of record in its ANDA litigation.

3. Repeat correspondent across the chain — INSUFFICIENT DATA. The Assignment Center correspondent-of-record field could not be retrieved for any of the five recorded events, so I can neither confirm nor deny recurrence of a single recording attorney/firm. No finding; flagged as an open retrieval gap.

4. Cascading transfers — NOT PRESENT. The recorded events are spaced across 2014–2021 (roughly annual and tied to specific credit-facility closings), not multiple chained LLC transfers inside 24 months. No common-principal shell cascade.

5. Pre-litigation transfer — NOT PRESENT. The '182 issued 2013‑11‑19; the earliest recorded event post-dating issuance is the 2014‑02‑13 Barclays security agreement, which arose from a June 2012 financing and sits outside any 6-month pre-suit window. The Jazz v. Amneal & Par action (D.N.J. 13‑391) asserting the "730 family" was filed in 2013, and the '182 was not yet issued at its inception. No ownership transfer was arranged to enable assertion.

6. Bankruptcy fire-sale — NOT PRESENT. Neither Orphan Medical nor Jazz filed Chapter 7/11. Orphan Medical was acquired in a solvent merger (June 24, 2005); Jazz remains a going concern. No patent sold out of a bankruptcy estate.

7. Privateering — NOT PRESENT. Jazz did not transfer the patent to an NPE to assert against competitors. Jazz is the named plaintiff in its own ANDA suits (D.N.J. 13‑391 and related) and itself settled with generic filers. The assertions are self-directed, not outsourced.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. Final recorded beneficiary of the last security agreement is U.S. Bank as Collateral Trustee; the equitable owner remains Jazz.

Verdict

Operating-company assertion.

Jazz Pharmaceuticals, Inc. — a commercial pharmaceutical manufacturer that sells Xyrem®/Xywav® (sodium oxybate), the products embodying the claims — owned this patent and asserted the "730 family" directly against generic ANDA filers (e.g., Jazz v. Amneal & Par, D.N.J. 13‑391). Every recorded assignment (Barclays 2014/2015, Bank of America 2015/2021, U.S. Bank 2021) is a security interest or a release thereof tied to the company's credit facilities, not an ownership transfer to a licensing vehicle; no NPE signal is present. Caveat: because I could not retrieve the Assignment Center reel/frame or correspondent fields, signals 2, 3, and 8 rest on the absence of any NPE-linked assignee in the documented chain rather than on a complete reel-level record — treat signals 3 as unresolved. The patent is also now expired (anticipated 2022‑12‑17), so there is no current assertion posture.

Verification link: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search by patent number 8589182); mirror at https://assignment.uspto.gov/patent/index.html.

Contradiction flag (per instructions): My prior "Patent summary" section listed the original family assignee as "Orphan Medical, Inc. / JPI Commercial, LLC" while the face-of-patent assignee is Jazz Pharmaceuticals, Inc. These are consistent, not contradictory — but note that the "Current Assignee" field on Google Patents lists Jazz Pharmaceuticals Inc for the '182 whereas sibling patents in the same family list JPI Commercial, LLC. Sibling-patent assignee data should not be read across to the '182 without the underlying reel; I did not conflate them.

I'll verify the patent number and dig into the specific prior-art references and the PTAB record before compiling the analysis.

Prior-Art Analysis — US Patent 8,589,182 B1

Scope discipline: This analysis is limited to US 8,589,182 B1 (application 13/595,676, filed 2012‑08‑27, granted 2013‑11‑19, priority 2002‑12‑17). Look‑alike numbers and family siblings (US 7,668,730; US 7,765,106; US 7,765,107; US 7,797,171; US 7,895,059; US 8,457,988; US 8,731,963; US 8,547,988) are excluded except where the record shows they share the identical specification/priority — those are self/family references, not prior art, and I flag them separately in §6. The citation list below is taken from the authoritative full text supplied and cross‑checked against USPTO PTAB records at ptacts.uspto.gov.

Consistency note (not a contradiction): The earlier "Patent summary" cites the appeal as 2017‑1671 and the "Litigation summary" cites 2017‑1675. Both are literally correct — the Federal Circuit opinion PDF (govinfo 17‑1675) resolves consolidated appeals 17‑1671, ‑1673, ‑1675, ‑1676, ‑1677, and ‑2075. No correction needed.

1. The legal frame that governs "anticipation" here

The '182 patent has a 2002‑12‑17 priority date and is governed by pre‑AIA 35 U.S.C. §102. Critically:

• The §102(b) critical date is 2001‑12‑17 (one year before priority). This is the date the PTAB and Federal Circuit used.
• A reference can anticipate only under §102 if it is a single prior‑art item disclosing every element of the claim (all‑elements rule).
• A reference filed/published after 2002‑12‑17 can only be prior art via §102(e) (U.S. patent/application by another, filed before the applicant's invention), and only if its filing date precedes Dec. 17, 2002.

Bottom line up front: Neither the examiner nor the PTAB ever found a single reference that anticipates claims 1–26 under §102. The claims were held unpatentable under §103 (obviousness) over the Advisory Committee Art ("ACA"). So the "§102 anticipation" column below reflects theoretical/potential §102 exposure, with the §103 reality noted. (Federal Circuit opinion, 895 F.3d 1347; Knobbe Martens)

2. TIER 1 — The prior art that actually invalidated the '182 patent

This is the "most relevant prior art" by outcome. In IPR2015‑00545 (Amneal + Par v. Jazz), the Board's sole ground was §103 over the ACA, and the Final Written Decision (2016‑07‑27) held claims 1–26 unpatentable; the Federal Circuit affirmed (July 13, 2018). (FWD; Valuck Declaration Ex. 1007)

Why this tier matters: the Federal Circuit confirmed these FDA materials were §102(b) "printed publications" because they were (1) disseminated via the Federal Register notice, (2) available ≥2 months before the critical date, (3) hosted on a public federal website with no confidentiality expectation, and (4) targeted at the relevant POSA (a pharmacist or computer scientist). (National Law Review; McDermott)

3. TIER 2 — Closest patent art on the front page (structural analogs)

These are the patent citations with the greatest structural overlap with the independent claims.

Technical read: the Celgene S.T.E.P.S. patents ('501 and its siblings) are the most legally uncomfortable art for the '182 independent claims, because their claim 1 recites exactly the "register → counsel → determine → authorize the registered pharmacy to fill" loop that the '182 patent recast around a central pharmacy and abuse screening. The '182 patent survived the examiner over these, but only because the examiner focused on the "exclusive central pharmacy / exclusive database / abuse‑check" limitation (see the applicant's characterization in the POPR: "[T]he closest prior art of record does not teach … that all prescriptions … are processed only by the exclusive central pharmacy using only the exclusive computer database." — IPR2015‑00545 POPR). That is a §103 gap, not a clean §102 gap, and it is why the IPR was fought on §103.

4. TIER 3 — Full per‑reference table of front‑page patent citations

Effective dates judged against the 2002‑12‑17 priority and the 2001‑12‑17 §102(b) critical date. ("§102(b)" = published/filed before 2001‑12‑17; "§102(a)/102(e)" = before 2002‑12‑17 by filing.)

5. Non‑patent citations of independent significance

The NPL list (101 items) contains several dates before the critical date that are §102(b) candidates in their own right, beyond the ACA set:

The remaining NPL items are almost entirely prosecution‑history and litigation documents (office actions, responses, Markman briefs, ANDA notices, the Roxane complaints, etc.). Those are not prior art against the '182 claims; they are useful only for prosecution‑history estoppel and claim‑construction arguments.

6. References that are NOT prior art to the '182 patent (excluded)

• Family members sharing the 2002‑12‑17 priority: US 2005/0090425 A1; US 2010/0138237 A1; US 2005/0216309 A1; US 2005/0222874 A1; US 2012/0209623 A1; US 7,668,730 B2; US 7,765,106 B2; US 7,765,107 B2; US 7,797,171 B2; US 7,895,059 B2; US 8,457,988 B1. These are the same invention (Orphan Medical/Jazz), not "by another," and share the same priority — they cannot be §102 art against the '182 patent.
• The "Family Cites Families" tier (e.g., US 6,892,941 B2; US 6,753,794 B2; US 5,963,919 A; US 6,154,738 A; EP 0 334 187 B1; GB 9117029 D0; GB 9716003 D0; JP 2003‑184685 A; US 2006/0054682 A1) are largely unrelated mechanical/electrical/software references and carry no meaningful weight on the '182 claims.

7. Assessment: what "anticipates" versus what merely "suggests"

• No true §102 anticipation was ever established. The examiner allowed the parent claims over the cited art; the PTAB invalidated claims 1–26 only via §103 over the ACA, and the Federal Circuit affirmed on that basis. Therefore, any §102 mapping above is potential/arguable, not adjudicated.
• Strongest single‑reference (§102) candidates are the ACA Ex. 1005/1006 (Xyrem briefing booklet / distribution‑system video+transcript) for the GHB‑specific independent claims (1, 8, 15, 19), and US 6,045,501 (Celgene) for the generic "register → determine → authorize registered pharmacy to fill" loop.
• Strongest §103 art — and the art that actually controls the patent's fate — is the ACA set combined with the Clozaril/thalidomide registry art (Honigfeld, Elsayed) and Lilly (controlled‑substance tracking), the combination the Board and Federal Circuit sustained.
• Claims most exposed to any restricted‑distribution reference: 1, 8, 15, 19 (the independent claims) plus their abuse‑database dependents (4, 5, 11, 12, 17, 18, 22, 23).
• Claims least exposed: the GHB‑specific limitations (6, 7, 13, 14, 24, 25) and the single‑manufacturing‑site limitation (claim 15) require the ACA's Xyrem‑specific disclosures or the '182 specification itself — which is precisely why the ACA (Orphan Medical's own public Xyrem materials) was fatal.

8. Caveats and confidence

• High confidence: the IPR2015‑00545 record, the ACA as the controlling prior art, the §103 basis, the 2016‑07‑27 FWD holding claims 1–26 unpatentable, and the July 13, 2018 Federal Circuit affirmance (895 F.3d 1347).
• Medium confidence: the exact per‑document dates within the ACA set (Exs. 1003–1006). The Board used "publicly accessible on the FDA website no later than October 4, 2001," over two months before the Dec. 17, 2001 critical date; individual document creation dates (e.g., the July 13, 2001 transcript date) differ from the posting date.
• Lower confidence: precise §102(e) priority chains for a few 2003–2004 publications (notably the Lilly family, #35/#36); I have relied on the priority dates as listed literally in the citation record (2001‑11‑14) rather than reconstructing each §102(e) benefit claim.
• I found no 2026 Federal Circuit docket activity naming US 8,589,182; the controlling appellate decision remains 2018. Per your strict rule, I am not asserting any 2026 activity exists.

Sources: Google Patents US8589182B1; IPR2015‑00545 FWD; Valuck Declaration, Ex. 1007 (USPTO PTACTS); IPR2015‑00545 POPR; Federal Circuit opinion (govinfo); Knobbe Martens analysis; US 6,045,501 (Celgene); IPWatchdog summary.

I'll ground this obviousness analysis in the actual prior art cited on the patent page and the PTAB record for this specific patent. Let me verify the key references and the IPR2015-00545 final written decision.

Excellent grounding. Let me pull the FWD's actual claim-by-claim analysis and the alternative prior-art combination (Talk About Sleep, Honigfeld/Clozaril, Elsayed/thalidomide, Lilly).

Let me pull the FWD's specific treatment of the '182 claims, including the GHB/cataplexy and inventory-reconciliation limitations.

Obviousness Analysis — US 8,589,182 B1 under 35 U.S.C. § 103

Scope note / cross-reference discipline. This analysis builds on the two prior sections. Everything below refers literally to US 8,589,182 B1 (application 13/595,676), not to its family siblings (US 7,668,730; 7,765,106; 7,765,107; 7,797,171; 7,895,059; 8,457,988; 8,731,963), which have separate claims. I rely on (i) the prior-art references listed on the patent page itself, and (ii) the actual PTAB/Federal Circuit record for this patent, which is unusually probative because a tribunal has already adjudicated precisely this §103 question.

0. Flagged contradiction with the earlier sections

The Patent summary section stated it could not determine the appeal outcome and cited "appeal number 2017‑1671." The Litigation summary section correctly identified the affirmance at No. 2017‑1675, 895 F.3d 1347 (Fed. Cir. July 13, 2018). My searches confirm the Litigation summary: the Federal Circuit opinion appears at govinfo as ca13-17-01675, and the affirmance is widely reported. Google Patents' "2017‑1671" is a separate/parallel appeal number in the same consolidated set. Resolved in favor of the Litigation summary and the Federal Circuit record.

1. Governing standard and the person of ordinary skill

• Statute: pre‑AIA § 103(a). Critical date for § 102(b) is December 17, 2001 (one year before the Dec. 17, 2002 earliest priority).
• POSA (as found by the Board and accepted on appeal): "a pharmacist or computer scientist having familiarity with computerized drug distribution procedures." Jazz Pharm., Inc. v. Amneal Pharm., LLC, 895 F.3d 1347 (Fed. Cir. 2018).
• Framework: KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) — a combination of familiar elements according to known methods is obvious when it yields predictable results, and a "design incentive," "market demand," or "known problem" supplies the motivation to combine.

2. The prior-art corpus (as it appears on the patent page and in the IPR record)

The patent page also lists the underlying generic tracking/EMR references cited during prosecution and in the IPRs — US 5,845,255 (Advanced Health Med-E-Systems), US 5,924,074 (Azron electronic medical records), US 6,021,392 (Pyxis), US 6,112,182 (Healthcare Computer Corp.), US 2002/0042762 (McQuade), US 6,952,681 (Data Reduction Systems), US 2003/0229519 (Eidex — identifying fraud/abuse in prescription claims). These supply the "routine computerization of prescription data" backdrop.

3. Combination A — the ACA alone (the combination actually adjudicated)

Because the four ACA documents were prepared together for the same June 6, 2001 Xyrem® Advisory Committee meeting, discuss the same drug and the same restricted-distribution program, and were linked from a single FDA web page, the Board treated them as "a cohesive teaching" and found "ample motivation to combine." (FWD at 25–33.) Under KSR, combining documents that describe one program is not even a true "combination" problem.

Claim-by-claim mapping (ACA)

Claim 1 (independent):

• 1.1 "single computer database… from any and all patients… all prescriptions": ACA discloses a single national pharmacy receiving Xyrem® prescribing forms "necessary in order for the prescriptions to be filled," described as a "single, central pharmacy" with a "central data repository." POSA would understand such a closed-distribution system handling large volumes of patient/prescriber data must be computerized (transcript shows a pharmacist at a computer terminal; slide 146).
• 1.2 patient identification: ACA's patient-registry application contains name, address, telephone, DOB, gender, SSN, record number.
• 1.3 any-and-all prescribers + authorization: ACA requires registration of "every patient and prescribing physician" in a secure database; it explicitly discloses checking the DEA database and the relevant state medical board for the prescriber.
• 1.4 maintain abuse/misuse/diversion information: ACA describes "close surveillance… to ensure that patients don't go from doctor to doctor trying to get refills"; "information is available prior to filling the prescription so appropriate pharmacist intervention can occur."
• 1.5 abuse-check + authorization condition: ACA discloses pharmacist intervention keyed to pre-fill database information — i.e., the record is consulted before filling.

Claim 8 (single-trademark variant): ACA's drug is Xyrem® — a single trademark — and the "may suggest" threshold is met by the same surveillance disclosures. FWD: claims 8 and 15 are "very similar to claim 1," and the ACA discloses the differing aspects.

Claim 15 (single-site + GHB/cataplexy variant): ACA discloses Xyrem® is manufactured at a single site, is mailed to the patient (the "providing" step), is a GHB drug product, and treats cataplexy in narcolepsy patients. The added "wherein" clause ("investigated and found not to involve abuse") is "insignificant" for the same reasons as element 1.5.

Claim 19 (multi-control variant): The ACA maps every sub-element:

• Pharmacy permitted based on ≥2 of four controls: processing a prescription enrollment form (ACA); providing educational materials ("Xyrem Patient Success Program"); verifying medical necessity (letter/certificate of medical necessity; diagnosis verification).
• DEA number + state license current, no pending disciplinary actions: ACA discloses checking the DEA/NTIS database and the state medical board.
• Verifying ≥2 of name / address / education received / quantity / dosing: ACA discloses verifying patient name and address by calling the physician's office, and a multi-faceted educational program; transcript: "when that prescription comes in they will call the prescribing physician's office to determine that, in fact, that patient is real…"; slide 153: specialty pharmacy will "Verify the Rx."

Claim 26 (inventory reconciliation): The FWD expressly adopted Petitioner's proofs that the ACA discloses the steps recited in claims 1–18 and 26. The ACA's central data repository plus the single-site/central-pharmacy consignment model supports pre-shipment cycle counting (the specification's own step 266).

Dependent claims 2–7, 9–14, 16–18, 20–25: adding delivery (ACA mails the drug), pharmacy data entry (central pharmacy), selective blocking (DB access denial), abuse-pattern blocking, GHB (ACA: Xyrem is GHB), and GHB-treats-cataplexy (ACA). The Board found these disclosed and noted Patent Owner did not challenge them except the "wherein" clause in claims 7/14/25.

Result: PTAB Final Written Decision, July 27, 2016 — claims 1–26 unpatentable as obvious over the ACA; rehearing denied; affirmed, Jazz v. Amneal, 895 F.3d 1347 (Fed. Cir. July 13, 2018). (FWD PDF; Fed. Cir. opinion; Duane Morris alert.)

4. Combination B — TAS + Honigfeld + Elsayed + Lilly (the alternative ground)

This is the more classically "multi-reference" §103 theory and is useful as an independent basis.

Reference roles and motivation to combine

1. Talk About Sleep supplies the problem frame and the central-pharmacy architecture specific to Xyrem®: "Xyrem will be available through a specialty distribution system that will utilize a central pharmacy…"; physician faxes Rx to the central pharmacy; pharmacy verifies with physician and patient. TAS is the closest art to the claimed application because it describes the claimed central-pharmacy distribution of the very drug at issue.
2. Honigfeld (Clozaril National Registry) supplies the centralized manufacturer-maintained computerized registry with restricted dispensing — all patients, prescribers and pharmacies register; prescriptions "may be filled only at participating pharmacy service providers registered with the manufacturer"; the registry is used to monitor and intervene. This is the claimed "single computer database … all prescriptions … any and all prescribers."
3. Elsayed supplies computer implementation and the education/consent machinery — registering prescribers, pharmacies and patients in "computer readable storage media," prescriber counseling, informed-consent forms, educational materials, and using the media to deny access/dispensation.
4. Lilly supplies the abuse-check-and-authorize step — comparing a new prescription against the patient's stored medication history and having the pharmacist accept or decline to fill, plus "aberrant use flag" and red-flagging.

Motivation

• Same field, same problem, same solution type. All four address controlling distribution of drugs prone to abuse, diversion, or severe adverse events. A POSA confronting GHB/"date-rape-drug" diversion (a problem the Federal Register notice itself flagged as "risk management") would look to the already-public restricted-distribution programs — Clozaril (Honigfeld), thalidomide/Accutane (Elsayed, and Celgene's S.T.E.P.S.).
• KSR design incentive. The FDA required a workable restricted-distribution program for Xyrem®; regulatory necessity is a classic "design incentive" and "known problem." The Board credited that a POSA "would have been familiar with the Federal Register and motivated to look for notices related to drug distribution, safety, or abuse prevention."
• Predictable results. Merging TAS's central pharmacy with Honigfeld/Elsayed's centralized registry, and adding Lilly's history-based accept/decline check, is the combination of familiar elements according to known methods producing predictable results.
• Routine computerization. One of ordinary skill (a pharmacist or computer scientist familiar with computerized drug distribution) would implement the registry and checks on a computer as a matter of routine design — supported by the generic EMR/tracking art on the page (US 5,845,255; US 5,924,074; US 6,112,182).

5. Why the "treatment" and "GHB/cataplexy" limitations do not save the claims

Claims 1, 8, 15, 19 are drafted as methods of treatment, but the novelty they assert resides entirely in the data-handling/distribution controls. Appending "delivering the drug to treat the patient" (claims 2/9/20), and "GHB… treats cataplexy" (claims 7/14/25; independent claim 15), does not confer nonobviousness because:

• The ACA itself discloses Xyrem® is GHB and is used to treat cataplexy/excessive daytime sleepiness in narcolepsy; and
• Using a known drug for its known, FDA-approved indication is not an inventive step.

The Board's treatment of the "wherein" clause and the GHB limitations reflects exactly this: no separate technical contribution.

6. Secondary considerations (objective indicia) — all fail

The Valuck declaration addresses each; the Board's findings comport:

• Commercial success: No nexus. Xyrem's sales flow from the active ingredient's efficacy, not the distribution program; indeed Orphan stated the restricted program would "eliminate[] the opportunity to 'fill the retail distribution pipeline.'" And commercial success is weak evidence for FDA-regulated products.
• Long-felt need / failure of others: Not "persistent and unmet" — Clozaril, Accutane, and thalidomide restricted-distribution programs already existed (Honigfeld; Elsayed; Celgene S.T.E.P.S.). "There were already various risk management programs in place… by December of 2002."
• Unexpected results: None proffered beyond what the prior art disclosed.

7. Bottom line

All 26 claims of US 8,589,182 B1 would have been obvious under § 103(a) over either:

• (A) the ACA — the four FDA-advisory-committee documents constituting a cohesive public disclosure of the Xyrem® risk-management distribution system (the ground the PTAB adopted and the Federal Circuit affirmed: claims 1–26 unpatentable, 895 F.3d 1347); or
• (B) TAS in view of Honigfeld, Elsayed, and Lilly — the classic multi-reference combination (central-pharmacy distribution of Xyrem + centralized manufacturer registry + computer-implemented education/consent and access denial + history-based accept/decline abuse check).

The motivation to combine is supplied by (i) a common, recognized problem (diversion/abuse of a controlled substance and FDA-mandated risk management), (ii) direct teaching in analogous, well-publicized restricted-distribution programs, and (iii) predictable results from routine computer implementation — the KSR formulation.

Confidence and caveats

• High confidence: the claims, the prior-art corpus, and Combination A's outcome (FWD July 27, 2016; Jazz v. Amneal, 895 F.3d 1347 (Fed. Cir. July 13, 2018)), which I verified from the FWD text and the Federal Circuit opinion.
• Medium confidence on Combination B's ultimate adjudication: the Board reached and rejected/credited the TAS+Honigfeld+Elsayed+Lilly ground in the companion '106/'059 IPRs (via preliminary/institution records), and the petitions pressed it as a second ground for the '182 patent. I have not independently confirmed the Board's final written word on every sub-limitation of Combination B as applied specifically to the '182 patent as opposed to its siblings; treat Combination B as a well-supported analyst theory that mirrors the record rather than as a quoted holding.
• Caveat on reference dates: Lilly (US 2003/0093295, filed Nov. 14, 2001) is a US application publication; its availability as prior art depends on § 102(e)/invention-date framing, which the Board resolved in Petitioner's favor. I have not re-derived that date arithmetic here.
• No auto-correction performed: all patent/application numbers (e.g., 13/595,676; 8,589,182; 7,668,730; 895 F.3d 1347; the various D.N.J. docket numbers) are reproduced exactly as found.